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A B S T R A C T
Background: The UK Community Pharmacy Future group developed the Pharmacy Care Plan (PCP) service with
a focus on patient activation, goal setting and therapy management.
Objective: To estimate the eﬀectiveness and cost-eﬀectiveness of the PCP service from a health services per-
spective.
Methods: Patients over 50 years of age prescribed one or more medicines including at least one for cardiovas-
cular disease or diabetes were eligible. Medication review and person-centred consultation resulted in agreed
health goals and actions towards achieving them. Clinical, process and cost-eﬀectiveness data were collected at
baseline and 12-months between February 2015 and June 2016. Mean diﬀerences are reported for clinical and
process measures. Costs (NHS) and quality-adjusted life year scores were estimated and compared for 12 months
pre- and post-baseline.
Results: Seven hundred patients attended the initial consultation and 54% had a complete set of data obtained.
There was a signiﬁcant improvement in patient activation score (mean diﬀerence 5.39; 95% CI 3.9–6.9;
p < 0.001), systolic (mean diﬀerence −2.90mmHg; 95% CI -4.7 to −1; p= 0.002) and diastolic blood pres-
sure (mean diﬀerence −1.81mmHg; 95% CI -2.8 to−0.8; p < 0.001), adherence (mean diﬀerence 0.26; 95%
CI 0.1–0.4; p < 0.001) and quality of life (mean diﬀerence 0.029; 95% CI 0.015–0.044; p < 0.001). HDL
cholesterol reduced signiﬁcantly and QRisk2 scores increased signiﬁcantly over the course of the 12 months.
The mean incremental cost associated with the intervention was estimated to be £202.91 (95% CI 58.26 to
£346.41) and the incremental QALY gain was 0.024 (95% CI 0.014 to 0.034), giving an incremental cost per
QALY of £8495.
Conclusions: Enrolment in the PCP service was generally associated with an improvement over 12 months in key
clinical and process metrics. Results also suggest that the service would be cost-eﬀective to the health system
even when using worst case assumptions.
1. Introduction
The increasing age of the population and increased life expectancy1
has led to general practice in England managing increasing numbers of
complex patients with more conditions and multiple medicines and
treatments, which require greater input from the healthcare system.2–4
With the current workload and resourcing issues in primary care not
likely to improve signiﬁcantly in the coming years, it has become ap-
parent that new models of care are needed to support professionals and
patients, particularly those with long-term conditions, to ensure that
high quality care is maintained.2 The Community Pharmacy Future
(CPF) team is a partnership of four UK multiple pharmacy companies
(Boots UK, Lloyds Pharmacy, Rowlands Pharmacy and Well) that col-
laborated to develop, implement and evaluate new models of care in
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community pharmacy to support the primary care team in managing
patients with long-term conditions. Previous CPF services have focused
on chronic obstructive pulmonary disease and patients taking four or
more medicines, and have demonstrated signiﬁcant improvements in
medicines adherence and quality of life.5,6 The aim of this project was
to extend this work to provide more patient-centred care across a wider
patient group with multi-morbidities, and over a longer period of time.
In response to the increasing prevalence of long term conditions in
developed countries and concerns regarding the sustainability of cur-
rent models of care, there is a transition from a “healthcare professional
knows best” viewpoint to a more patient centred approach which em-
powers patients to manage their own condition.7–10 Patient activation is
increasingly seen as an important concept in relation to person-centred
care and central to encouraging self-care behaviours. Patient activation
was ﬁrst conceptualised and used as a tool for healthcare conversations
in 2004 by Hibbard et al.11,12 ‘Patient activation’ describes the
knowledge, skills and conﬁdence a person has in managing their own
health and healthcare. With an increased activation level, patients are
more likely to have clinical indicators in the normal range and have a
positive experience of care.13 Increased activation has also been shown
to be related to reduced healthcare costs particularly with respect to
fewer secondary care admissions14–16 and re-admissions.17 Examples of
interventions aimed at increasing patient activation include tailored
coaching, peer support and self-management guidance.13 A central
component is the breaking down of large healthcare targets into small,
manageable goals that can be addressed more easily by the patient.
These can then be monitored and allow the patient to build conﬁdence
in managing their own health as changes are more readily observed.
Conversely, for patients with a high, or increasing, level of activation,
more stretching and challenging goals and actions can be agreed.
With the growing evidence for the impact of patient activation in
healthcare, the CPF team developed the Pharmacy Care Plan (PCP)
service with a focus on patient activation, goal setting and therapy
management. The aim of this paper is to evaluate the PCP service and
assess its cost-eﬀectiveness from a UK National Health Service (NHS)
perspective.
2. Methods
Approval for this service evaluation was provided by the Faculty of
Medicines and Health Sciences Ethics Committee at the University of
East Anglia (UEA) before commencement.
The pharmacist training and intervention have been described in
detail in a previous publication.18 Brieﬂy, 38 pharmacies in Northern
England, including independent pharmacies, provided the PCP service
to patients over 50 years old and prescribed one or more medicines
(including at least one for cardiovascular disease or diabetes type 1 or
type 2). Patients were excluded if they had experienced a myocardial
infarction, transient ischaemic attacks, angina or stroke. Identiﬁcation
was via the pharmacy medication record or referral from the general
practitioner (GP), and patients were consented to participate. The in-
itial screen of suitability was performed by the pharmacist with access
to the patient medication record. The initial approach was made by
either the pharmacist or a technician who had received the training.
The service was operational between February 2015 and June 2016.
Patients were oﬀered multiple consultations with the pharmacist
over the course of 12 months. The patient was asked to commit to
meeting with their pharmacist at baseline, six and 12 months to allow
for follow-up and data collection. However, there were no restrictions
on how many times the patient could meet the pharmacist outside of
these ‘core’ consultations. This was decided between the patient and
pharmacist according to need and suggested to coincide with monthly
prescription collection.
The initial consultation consisted of several elements:
• Medication review using relevant National Institute of Health and
Care Excellence (NICE) guidance19–21 and a modiﬁed STOPP/START
tool22 previously used in a community pharmacy setting.5
• Obtaining data to calculate the patient's cardiovascular risk using
the QRISK2 (2016) instrument23 e.g. blood pressure, lipid proﬁle.
• Provision of adherence advice including inhaler technique (where
necessary).
• Development of a jointly-produced personalised care plan that in-
cluded agreed goals for their condition and treatment.
• Referral to the GP where necessary.
• Referral to other services e.g. smoking cessation, weight loss, where
necessary.
At subsequent consultations, the patient and pharmacist discussed
progress with the goals agreed at the initial session and made further
recommendations. Clinical measures were obtained and reviewed with
the patient and, if appropriate, new goals and/or actions were agreed.
3. Data collection
The following data were requested from patients at baseline, six and
12 months via questionnaire and were used to inform the consultation
at each stage:
• Patient reported medication adherence (Morisky MMAS-8)24–26
• Quality of life measure (EuroQol EQ-5D-5L)27
• Patient Activation Measure® (PAM®, 10 item version), designed to
measure patient knowledge, skills and conﬁdence in managing their
health12
Additional data collected by the healthcare assistant (HCA), to en-
able the calculation of QRisk2 score, included:
• Blood pressure (lowest of two measurements used)
• Non-fasting lipid proﬁle (total cholesterol, HDL cholesterol)
• Weight and height
• Smoking status (options aligned with QRisk2)
• Condition status
Blood pressure measurements were obtained using machines routi-
nely available in each pharmacy. Point of care testing, using the
CardioChek®, Polymer Technology Systems Inc. was used to obtain the
cholesterol results.
4. Clinical and process data analysis
All data were entered by pharmacists providing the service to an
online database used routinely in the UK for the provision and eva-
luation of community pharmacy services. Anonymised data were ﬁrst
assessed for accuracy via visual, range and logic checks by the CPF team
responsible for implementing the service. This involved selecting a
sample of entries and contacting pharmacists to conﬁrm values entered
to the database, to ensure the information received by the evaluation
team was accurate. Anonymised data were then transferred to the UEA
for analysis.
The MMAS-8 measure of adherence was scored according to in-
structions provided by Morisky and colleagues, with a ﬁnal score of
8=high adherence, 6-< 8=medium adherence and< 6= low ad-
herence.24–26 The PAM® score was derived from the ten questions of the
instrument resulting in a score of 0–100 (where a higher score denotes
greater activation).12 Depending on the score, patients were then as-
signed a PAM level from one (low activation) to four (high activation)
using algorithms supplied by Insignia Health LLC. QRisk2 data was
collected by pharmacists and calculated by the CPF team using the 2016
risk calculator at the end of the study.28
Descriptive statistics were reported for quantitative data: mean and
standard deviation for interval data, median and interquartile ranges
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for ordinal or skewed interval data, and number and percent for nom-
inal data. To compare the baseline characteristics of those who com-
pleted the service evaluation and those who did not, independent
samples t-tests or Mann-Whitney U tests were performed, depending on
the nature of the data. Paired-samples t-test was used to compare before
and after interval data. Mean diﬀerences (95% CI) were presented
alongside the associated p-values. The level of signiﬁcance was set at
0.05.
5. Cost-eﬀectiveness
5.1. Intervention costs
Average times (total patient contact and non-contact) for both the
pharmacist and health care assistant (HCA) were estimated for each of
the consultations (baseline, six and 12-months, plus any interim con-
sultations). Unit costs (cost per hour of employment29) were then as-
signed to these times in order to enable the mean cost of each con-
sultation to be estimated. These and all subsequent costs are reported
from an NHS perspective in £GBP for the 2014-15 ﬁnancial year (no
discounting has been undertaken as the follow up period is 12 months).
Per participant attendance rates (recorded by the pharmacist and HCA
staﬀ who delivered the intervention) were then combined with the
estimated cost per consultation, enabling the total cost of all con-
sultations to be estimated for each participant.
Pharmacist and HCA staﬀ were provided with training in order to
deliver the intervention and certain equipment was required for each of
the pharmacies that participated.18 These items were documented
along with associated costs (pharmacist and HCA times were costed as
above). This enabled the cost of equipment, associated consumables for
cholesterol testing, and training to be estimated. These costs were
subsequently equally apportioned across all participants who received
the intervention, and then added to the aforementioned per patient
total consultation cost in order to estimate the total intervention cost
for each participant.
5.2. Other (non intervention) NHS costs
Participants were asked to report the total number of:
• Days in hospital
• GP visits
• Practice nurse visits
• Hospital doctor visits.
At the initial consultation (baseline), the period over which patients
were asked to report such visits was the previous 12 months. At each
subsequent consultation, participants were also asked to report the
number of such visits since their last consultation. For those that re-
ported such information at the 12-month review, and any previous
consultations, it was thereby possible to estimate the total number of
the above four types of visits for the 12 months since their initial
consultation. Unit costs29,30 were subsequently assigned to these visits,
and they were summed together in order to provide an estimate of total
other (non-intervention) NHS costs. For the 12 months prior to the
initial consultation, this provided an estimate of the total NHS costs, as
there were no intervention costs prior to the baseline consultation. For
the 12 months after the baseline consultation, total other (non inter-
vention) NHS costs were added to the aforementioned total interven-
tion costs in order to estimate the total NHS costs. The diﬀerence be-
tween the total NHS costs before the initial consultation, compared to
the total NHS costs in the subsequent 12 months, provided an estimate
of the incremental cost associated with the intervention. This con-
stituted a before and after analysis, where it is assumed that any change
was due to the intervention.
5.3. Outcomes
In line with the NICE methods guide,31 quality of life was measured
using the EQ-5D-5L.27 Participants were asked to complete this at the
baseline consultation and again at the six and 12-month follow-up.
Responses were converted into utility scores (a scale where zero is equal
to death and one is full health)32 using an EQ-5D-5L value set for
England.33 Quality Adjusted Life Year (QALY) scores were subsequently
calculated for the 12 months after the baseline consultation using the
area under the curve approach,34 where baseline adjustment was un-
dertaken in order to estimate the QALY gain over the 12 months since
the initial consultation. The QALY gain could thereby be estimated for
all participants who at least completed the EQ-5D-5L at the baseline
consultation and the 12-month review.
5.4. Analyses
In the base-case analysis, a complete case approach35 was under-
taken, whereby participants were only included if the incremental cost
and incremental QALY gain could be calculated. This required a re-
sponse to, at least, the aforementioned questions relating to the EQ-5D-
5L and four visit types at both the baseline consultation and the 12-
month review, as well as information relating to the number of inter-
vention consultations attended.
The mean per participant incremental cost and QALY gain was es-
timated and subsequently used to estimate the incremental cost-eﬀec-
tiveness ratio (ICER) (mean incremental cost/mean incremental QALY
gain).32 In the UK, NICE refers to a cost-eﬀectiveness threshold (λ)
value of £20,000–30,000 per QALY,31 and we considered that an esti-
mated ICER below £20,000 would indicate that the intervention con-
stituted value for money.
In order to estimate the level of uncertainty associated with the
decision regarding cost-eﬀectiveness, the cost eﬀectiveness accept-
ability curve (CEAC)36 was estimated. The CEAC estimates the prob-
ability of the intervention being cost-eﬀective, and this probability was
speciﬁcally estimated at a λ (threshold) value of £20,000 per QALY.
Additionally, bootstrapping37 (5000 replications were resampled with
replacement) was performed to estimate the 95% conﬁdence interval
(CI) (based on the percentile method38) associated with the incremental
cost, incremental QALY gain and the ICER. For the ICER these were
presented in the net beneﬁt format as there is the potential for negative
ICERs to be misinterpreted.39 Net beneﬁts were calculated using a λ
value of £20,000 per QALY, where a positive value would indicate that
the intervention was estimated to be cost-eﬀective at that threshold.39
5.5. Sensitivity analyses
We undertook a number of sensitivity analyses32 to assess the ro-
bustness of conclusions to changes in key assumptions that were in-
cluded in the above described base-case32 analysis. Within the ﬁrst
sensitivity analysis (best case), we excluded the intervention costs re-
lating to training and equipment, on the assumption that these costs
would not need to be incurred again if the intervention continued to be
provided in current sites (we acknowledge that the results would not be
applicable to new sites as they would likely require training/additional
equipment). In the second sensitivity analysis (worst case) all partici-
pants were included and where data was missing it was assumed that
the intervention had had no eﬀect (a QALY gain of zero), but a cost for
the intervention and other (non intervention) NHS costs was included.
When considering these sensitivity analyses, in line with the re-
commendation when using ‘extreme but plausible’ upper and lower
bounds,32 we particularly focus upon whether the decision about
whether the intervention is estimated to constitute value for money
would change from that in the base-case, where it has been argued40
that decisions regarding cost-eﬀectiveness should be made on the basis
of mean values, rather than associated levels of uncertainty.
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6. Results
A total of 700 patients attended the initial consultation and had a
complete set of clinical and process data obtained. At month 12, 378
(54%) patients (spread across 38 pharmacies) remained in the service
and had a complete set of clinical data. A CONSORT diagram is pro-
vided in Fig. 1. The patients that completed the service received an
average of 2.93 (range 1–7) consultations, mean (SD) age was 68 (8.1)
years, with 212 (56.1%) female patients and 371 (98.1%) classifying
themselves as white. Patients who left the service before the 12-month
consultation were similar for most clinical and process measures, with
the exception that they had a signiﬁcantly higher BMI, lower patient
activation (PAM® score), lower adherence to medicines, lower quality of
life and more GP visits (see Table 1). Reasons for drop-out were col-
lected from 220 (31.4%) patients, with the main reasons stated as a lack
of time (24.5%), patient didnot feel the need for the service (16.4%)
and patient did not want to be bothered again (15.9%).
6.1. Clinical and process data
Table 2 shows the changes in all outcome measures from baseline
(all patients and those completing the service) to 12-months. It shows a
signiﬁcant improvement in systolic and diastolic blood pressure, PAM®
score, adherence and quality of life. HDL cholesterol reduced sig-
niﬁcantly and QRisk2 scores increased signiﬁcantly over the course of
the 12 months. Further analysis showed that the increase in mean
QRisk2 over this time period was largely due to patients' (recorded)
condition status changing. Controlling for changes in condition status,
the mean diﬀerence became non-signiﬁcant (0.48 (−0.2–1.1). Smoking
status did not change appreciably over the course of 12 months. The
number of patients with a high blood pressure (> 140/90mmHg) re-
duced over the course of the study. The percentage of patients
achieving the two higher patient activation level and adherence levels
also increased over the 12 months, while the percentage of patients in
the lower levels of activation and adherence showed a corresponding
decrease.
In terms of goals agreed between the patient and pharmacist, 669
patients (93.2% of 718 who had any baseline interaction) set one or
more goals. Overall, 1181 goals were set, ranging from one to six per
patient, with an average of 1.8 goals per patient. Of these, 410 (61.3%)
patients reviewed 608 goals, of which 263 patients (61.4%) achieved
359 goals (59.0%). The majority of goals set related to weight (377
patients setting 380 goals in this area, representing 32.2%) and con-
dition control (265 patient set 322 goals, representing 27.3%; Table 3).
The largest number of goals that patients indicated had been achieved
were primarily concerned with weight and condition control (Table 3).
6.2. Cost-eﬀectiveness
In total, 378 completed the EQ-5D-5L at both the baseline and 12-
month follow-up point (enabling the incremental QALY gain to be
Fig. 1. CONSORT diagram.
Table 1
Baseline and drop-out data comparison.
Measure N Baseline result,
completed 12 months
N Drop outs, between baseline and FU p-value
Weight (Kg) Mean (SD) 378 83.4 (17.8) 322 85.5 (19.4) 0.114a
BMI (Kg/m2) Mean (SD) 378 30.2 (5.8) 322 31.4 (6.3) 0.011a
Systolic BP (mmHg) Mean (SD) 378 139.5 (18.1) 322 141.7 (18.6) 0.126a
Diastolic BP (mmHg) Mean (SD) 378 78.4 (10.1) 322 79.4 (11.3) 0.186a
High BP (≥140/90mmHg) N (%) 378 196 (51.9) 322 183 (56.9)
Total cholesterol (mmol/L) Median (IQ) 378 3.9 (3.2–4.8) 322 3.8 (3.1–4.8) 0.643b
HDL cholesterol (mmol/L) Median (IQ) 378 1.2 (0.9–1.6) 322 1.2 (0.9–1.5) 0.250b
Cholesterol/HDL ratio Median (IQ) 378 3.0 (2.4–4.2) 322 3.1 (2.4–4.4) 0.616b
QRisk score Median (IQ) 370 24.2 (14.8–34.8) 306 25.5 (17.3–37.2) 0.073b
High QRisk score N (%) 370 230 (62.2) 306 208 (68.0)
PAM Score Mean (SD) 378 60.3 (14.2) 322 57.8 (14.3) 0.022a
Level 1 N (%) 378 46 (12.7) 322 50 (15.5)
Level 2 N (%) 92 (24.3) 90 (28.0)
Level 3 N (%) 181 (47.9) 140 (43.5)
Level 4 N (%) 57 (15.1) 42 (13.0)
MMAS-8 Median (IQ) 378 8.0 (6.2–8.0) 322 7.0 (6.0–8.0) 0.028b
Low N (%) 378 75 (19.8) 322 71 (22.0)
Medium N (%) 113 (29.9) 115 (35.7)
High N (%) 190 (50.3) 136 (42.2)
EQ-5D-5L score Mean (SD) 378 0.799 (0.203) 322 0.752 (0.243) 0.005a
EuroQol VAS Mean (SD) 378 74.30 (20.02) 322 70.52 (20.27) 0.013a
Total cost Mean (SD) 249 592.08 (1051.92) 436 673.51 (1528.30) 0.411a
Days in hospital Mean (SD) 249 0.76 (2.86) 436 1.02 (4.37) 0.398a
GP visits Mean (SD) 249 3.41 (3.00) 436 4.18 (4.66) 0.019a
Practice nurse visits Mean (SD) 249 2.24 (2.40) 436 2.41 (2.96) 0.442a
Hospital doctor visits Mean (SD) 249 1.82 (2.86) 436 1.58 (2.82) 0.272a
a ISTT.
b MWU.
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estimated), 249 provided data on the four visit types at both these time
points (enabling the incremental cost to be estimated) and 246 pro-
vided data that enabled both the incremental cost and incremental
QALY gain to be estimated and were thereby included in the subse-
quently reported base-case analysis.
6.2.1. Costs
Estimated unit costs (cost per hour of employment) for the phar-
macist and HCAs are reported in Table 4. The total intervention cost
was estimated to be £160.67 (see Table 5, where the costs relating to
the component parts of training, equipment and intervention contacts
are reported). For the 249 that provided resource use data on the four
visit types at both baseline and 12-month follow-up (enabling the in-
cremental cost to be estimated, see Table 6), it can be seen that there
was no signiﬁcant diﬀerence between the previous 12-month levels of
resource use at both these time points. As such, the total other (non
intervention) NHS costs, in the previous 12 months, were not sig-
niﬁcantly diﬀerent between baseline and 12 months (see Table 6).
However, total NHS costs were higher in the 12-month follow-up period
(see Table 6), largely due to the intervention cost, and in the base-case
analysis the mean incremental cost associated with the intervention was
estimated to be £202.91 (95% CI 58.26 to £346.41) (see Table 6).
6.2.2. Outcomes
For the 378 with complete EQ-5D-5L data, the mean improvement
in quality of life was estimated to be 0.029 (95% CI 0.015–0.044) (see
Table 2). For those who also had incremental cost data, and were
thereby included in the base-case analysis, the mean incremental QALY
gain was estimated to be 0.024 (95% CI 0.014 to 0.034) (see Table 7).
6.2.3. Cost-eﬀectiveness
Based on the aforementioned incremental cost and incremental
QALY gain, in the base-case analysis, the ICER was estimated to be
£8495 per QALY, where the 95% CI for the incremental net beneﬁt was
estimated to be below the £20,000 per QALY threshold value (see
Table 7). Additionally, according to the CEAC, there was a 97% prob-
ability that the intervention was cost-eﬀective at the £20,000 per QALY
threshold value (see Table 7 and Fig. 2).
6.2.4. Sensitivity analyses
The ICER, associated 95% CI and CEAC value were estimated to be
more favourable in the ‘best case’ sensitivity analysis when training and
equipment costs were excluded from the intervention costs (see Table 7
Table 2
Clinical data for patients in receipt of the PCP service.
Clinical measure Measure N All participants at
baseline
N Baseline result for those who
completed FU
Follow-up result at 12
months
Mean diﬀerence (95%
CI)
P-value*
Weight (Kg) Mean (SD) 700 84.4 (18.6) 378 83.4 (17.8) 82.8 (17.5) −0.53 (−1.1–0.0) 0.067
BMI (Kg/m2) Mean (SD) 700 30.8 (6.1) 378 30.2 (5.8) 30.1 (5.4) −0.19 (−0.4–0.0) 0.112
Systolic BP (mmHg) Mean (SD) 700 140.5 (18.3) 378 139.5 (18.1) 136.6 (18.8) −2.90 (−4.7 to −1.) 0.002
Diastolic BP (mmHg) Mean (SD) 700 78.9 (10.7) 378 78.4 (10.1) 76.6 (10.8) −1.81 (−2.8–−0.8) <0.001
High BP (≥140/
90mmHg)
N (%) 700 379 (54.1) 378 196 (51.9) 172 (45.5)
Total cholesterol (mmol/
L)
Median (IQ) 700 3.8 (3.1–4.8) 378 3.9 (3.2–4.8) 3.9 (3.1–4.5) −0.07 (−0.2–0.0) 0.225
HDL cholesterol (mmol/
L)
Median (IQ) 700 1.2 (0.9–1.6) 378 1.2 (0.9–1.6) 1.2 (0.9–1.5) −0.10 (−0.2–0.0) 0.001
Total/HDL Cholesterol
ratio
Median (IQ) 700 3.1 (2.4–4.3) 378 3.0 (2.4–4.2) 3.1 (2.5–4.4) 0.16 (−0.0–0.4) 0.119
QRisk score Median (IQ) 676 25.3 (16.0–36.0) 370 24.2 (14.8–34.8) 26.0 (16.5–37.0) 2.22 (1.4–3.1) <0.001
High QRisk score N (%) 676 438 (64.8) 370 230 (62.2) 250 (67.6)
PAM® Score Mean (SD) 700 59.1 (14.3) 378 60.3 (14.3) 65.7 (15.4) 5.39 (3.9–6.9) <0.001
Level 1 N (%) 700 98 (14.0) 378 48 (12.7) 14 (3.7)
Level 2 N (%) 182 (26.0) 92 (24.3) 60 (15.9)
Level 3 N (%) 321 (45.9) 181 (47.9) 204 (54.0)
Level 4 N (%) 99 (14.1) 57 (15.1) 100 (26.5)
MMAS-8 Median (IQ) 700 7.0 (6.0–8.0) 378 8.0 (6.2–8.0) 8.0 (7.0–8.0) 0.26 (0.1–0.4) <0.001
Low N (%) 700 146 (20.9) 378 75 (19.8) 40 (10.6)
Medium N (%) 228 (32.6) 113 (29.9) 135 (35.7)
High N (%) 326 (46.6) 190 (50.3) 203 (53.7)
EQ-5D-5L score Mean (SD) 700 0.778 (0.223) 378 0.799 (0.203) 0.829 (0.199) 0.029 (0.015–0.044) <0.001
EuroQol VAS Mean (SD) 700 72.56 (20.21) 378 74.30 (20.02) 77.46 (20.70) 3.15 (1.15–5.15) 0.002
Table 3
Goals set and achieved by patients enrolled in the PCP service.
Goal
Category
Number (%)
patients who
set goals
Number (%
of total)
goals set
Range
per
patient
Number patients who
achieved goals (%
patients who
achieved goals)
Weight 377 (52.5) 380 (32.2) 1–2 104 (27.6%)
Condition
control
265 (36.9) 322 (27.3) 1–4 92 (31.7%)
Exercise/
activity
155 (21.6) 158 (13.4) 1–2 45 (29.7%)
Diet 77 (10.7) 77 (6.5) 1 24 (31.2%)
Adherence 71 (9.9) 73 (6.2) 1–2 27 (38.4%)
Smoking 48 (6.7) 48 (4.1) 1 13 (27.1%)
Knowledge 44 (6.1) 45 (3.8) 1–2 22 (48.9%)
Mental health 43 (6.0) 43 (3.6) 1 8 (8.6%)
Alcohol 12 (1.7) 12 (1.0) 1 6 (50.0%)
Other 23 (3.2) 23 (1.9) 3 4 (17.4%)
Total 669 (93.2) 1181 1–6
Table 4
Unit costs attached to diﬀerent items of resource use, with associated source.
Item Estimated unit cost
Pharmacist (Band 6, cost per hour of employment,
including overheads)a
£42.08
Health care assistant (cost per hour of employment,
including overheads)a
£22.61
GP visita £37.00
Hospital admission (cost per bed day)b £302.97
Hospital out-patient visitb £139.00
Practice nurse visita £12.09
a Based on Curtis.29
b Based on the National Schedule of Reference Costs.30
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and Fig. 1). This reﬂects the fact that together the training and equip-
ment costs are estimated to constitute the majority of the intervention
costs (see Table 5), and if, for example, not all of these costs had been
loaded on trial participants, then more favourable results might have
been seen in the base-case. In the second (worst case) sensitivity ana-
lysis, for those participants who had missing data in relation to other
(non intervention) NHS costs, a cost of £39.76 was assigned to this
variable (this is the mean value for those who had complete data on this
variable, see Table 6). Even in this worst-case (where, when data was
missing, it has been assumed that there was no change in quality of life
and a cost for other (non intervention) NHS services has been included,
as participants may have still been referred to the GP/other services)
the ICER was still estimated to be below the £20,000 per QALY value
(see Table 7). There was however an increased level of uncertainty, as
reﬂected in the 95% CI associated with the ICER (see Table 7) and the
CEAC (see Fig. 1).
7. Discussion
For most patients, enrollment on the pharmacy care plan (PCP)
service was associated with an improvement over 12 months in key
clinical, process and humanistic data. Improvements were observed in
patients for systolic and diastolic blood pressure, patient activation,
adherence and quality of life. The service was also estimated to be cost-
eﬀective from the perspective of the NHS. The mean estimate was<
£20,000/QALY even in what might be considered a worst case sce-
nario.
There were several strengths and limitations associated with this
evaluation. This was a before-and-after study and as such, any changes
in outcome measures cannot automatically be attributed directly to the
intervention as no control group was used. However, this represents a
pragmatic design in a setting where it may be diﬃcult to recruit pa-
tients to a control group. In order to estimate cost-eﬀectiveness, data
was collected from patients on their resource use in the 12 months prior
to commencing the service. This resource use data, along with ad-
herence, patient activation and quality of life are all patient self-re-
ported measures, which are subject to recognised limitations.41,42 To
address concerns over the nature of the study design, a worst case cost-
utility analysis was performed and this still produced positive results. A
limited NHS perspective was taken and certain items e.g. medication
usage were not requested as, in line with recommendations,43 we fo-
cused on what were expected to be the main cost drivers.
Almost 50% of the patients who started the service did not remain
until the end. Stated reasons for dropping-out included a lack of time
and feeling no need for the ongoing service. Indications from the out-
come data point to patients dropping out who were less activated, less
likely to take their medicines, had a lower quality of life and visited
their GP more. This will impact on the generalizability of the results and
Table 5
Intervention costs.
Component part Resources costed & participant attendance/assumptions Mean cost (£ per participant)
Training A pharmacist and health care assistant (HCA) from each of the 52 sites received a delegate pack (£30 per pack) and
attended a 1 day training event. Four such events were held, with two trainers (@£500 per day each), medical actors (@
£590 per day in total) and associated facilities (@£300 per day). Apportioned across all N= 718 attendees.
50.01
Initial consultation 15min patient contact time with a HCA, 30min patient contact time with pharmacist, 15min non-patient contact time by
the pharmacist for paperwork, etc. N= 718 attended.
33.70
Interim review(s) 10min patient contact time and 5min non-patient contact time with/by the pharmacist. A total of N=513 took place. 7.52
6 monthly review 15min patient contact time with a HCA, 15min patient contact time with pharmacist, 10min non-patient contact time by
the pharmacist for paperwork, etc. N= 486 attended.
15.69
12 monthly review 15min patient contact time with a HCA, 15min patient contact time with pharmacist, 10min non-patient contact time by
the pharmacist for paperwork, etc.. N=386 attended.
12.46
Equipment Cholesterol testing kit (£470 per site) and equipment to measure blood pressure (£40 per site), weight (£40 per site) and
height (£20 per site). Apportioned across all N= 718 attendees.
41.28
Total 160.67
See Table 4 for pharmacist HCA unit costs. NB N=718 as resource use data was available for more patients than data for clinical measures. Ten patients had baseline
resource data but no baseline clinical data were recorded, demonstrating that they did attend a baseline consultation. An additional 8 patients had data collected at
later time points, but no resource use or clinical data recorded for the baseline consultation, it was assumed that these 8 patients did have a ﬁrst consultation. These
18 patients were therefore excluded from the clinical analysis, but included for goals analysis and this analysis as they were shown or assumed to have also had a
baseline consultation.
Table 6
Mean (SD) levels of resource use data for particular health care services, with associated costs (£).
Measure N All participants at
baseline
N Baseline result for those who
completed FU
Follow-up result at 12
months
Mean diﬀerence (95% CI) P-value*
Days in hospital 685 0.93 (3.89) 249 0.76 (2.86) 0.96 (3.51) 0.20 (−0.29 to 0.70) 0.424
Cost 280.41 (1178.47) 229.96 (864.98) 290.80 (1064.84) 60.84 (−88.93 to 210.60) 0.424
GP visit 685 3.90 (4.15) 249 3.41 (3.00) 3.89 (3.67) 0.48 (−0.02 to 0.98) 0.062
Cost 144.43 (153.40) 126.31 (111.01) 143.99 (135.83) 17.68 (−0.89 to 36.25) 0.062
Practice nurse visits 685 2.34 (2.77) 249 2.24 (2.40) 1.88 (2.07) −0.35 (−0.67 to −0.04) 0.029
Cost 28.35 (33.45) 27.04 (29.04) 22.77 (24.99) −4.27 (−8.11 to −0.44) 0.029
Hospital doctor visits 685 1.67 (2.84) 249 1.82 (2.86) 1.52 (3.02) −0.30 (−0.29 to 0.70) 0.156
Cost 190.72 (324.87) 208.77 (327.44) 174.28 (346.27) −34.49 (−82.25 to
13.28)
0.156
Total other (non intervention) NHS
costs
685 643.91 (1374.10) 249 592.08 (1051.92) 631.84 (1317.61) 39.76 (−133.94 to
213.46)
0.653
Total NHS costs 685 643.91 (1374.10) 249 592.08 (1051.92) 814.96 (202,925.99) 222.89 (49.24–396.54) 0.012
At the initial consultation (baseline) participants were asked to report the total number of each item of resource use in the last 12 months. At each subsequent review
participants were asked to report the total number of each item of resource use, since their previous consultation/review where they reported such values. For those
who attended the 12 month review, the reported values over the 12 month follow up period have been summed. *Paired samples t-test.
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more work needs to be undertaken to understand reasons for not re-
maining in the service. To address the high attrition rate in future, the
service could be oﬀered to those most likely to keep attending, or the
pharmacist could explain to patients the importance of the service to
encourage their continued participation. A further factor that will in-
ﬂuence the generalizability of the results is the targeted recruitment of
patients with cardiovascular disease for the service in order to capture a
clinical outcome that was appropriate across all patients.
A further limitation of this study is the self-report nature of the
questionnaires measuring activation, adherence, resource use and
quality of life where patients were unblinded to the intervention.
However, these were used at baseline and follow-up and analysis fo-
cused on changes rather than absolute values. Despite this, patients may
have underestimated their resource use at baseline due to the 12
months period over which they were asked to recall visits (post baseline
patients were asked to report resource use since their last visit). That
said, other studies have used such a time period and there is no con-
sensus on aspects such as the optimal time period within patient re-
source use questionnaires.44
Finally, a strength of this study was the long follow-up of patients.
In previous services by the same team follow-up has been limited to six
months.5,6 However, in this service patients were enrolled for a total of
12 months. This indicates that changes observed over this time are
more likely to be maintained.
With the exception of QRisk2 and HDL cholesterol, clinical in-
dicators improved in patients enrolled in the PCP service. The increase
in QRisk2 was observed as being largely due to changes in condition
status, something that cannot necessarily be attributed to the pharma-
cist providing the service. Indeed, it may be that more conditions were
recorded as more consultations took place, simply because the patient
divulged more information to the HCA/pharmacist. No data was
collected to determine whether the pharmacist was responsible for
identifying any of these additional diagnoses. In addition, the reduction
in HDL cholesterol over the 12 month service is surprising and requires
further work to understand whether this was as a result of the diet and
lifestyle goals agreed between the patient and pharmacist or whether
something else was responsible. Without a control group, it is diﬃcult
to determine this information with any certainty.
Although the aforementioned diﬀerences were small, it indicates
movement in the right direction. This improvement may be linked to
goals agreed between the patient and pharmacist with the majority
focusing on weight and control of their conditions. The use of goal
setting to target key behaviours such as weight loss, diet and exercise is
one that has been explored repeatedly in the literature.45,46 When
looking at the goals achieved by patients, those relating to knowledge
and adherence were among the highest achieved categories, whereas
only about 1 in 3 patients who set weight goals indicated that they had
achieved them. These results seem to correlate with the clinical out-
comes, as weight did not change signiﬁcantly, but adherence and pa-
tient activation (which includes understanding) did. Further research
should be undertaken on the types of goals set as some of these set in
this service were achievable and measurable and some were not. This
may imply that more training of the pharmacist is required to help
patients set SMART goals as part of the service.
In terms of activation and adherence, patients demonstrated a sig-
niﬁcant increase in both over the course of 12 months. Improvements in
adherence scores have previously been linked to improved clinical
outcomes in diabetes,47 hypertension48 and asthma and COPD49,50
which may be responsible for some clinical improvements observed in
this evaluation. Patient activation is also important in this group of
patients as condition management will involve changes to diet, lifestyle
and exercise habits for which the patient will need to be motivated to
Table 7
Base-case and sensitivity Analysis.
N Mean incremental cost (95% CI) Mean QALY gain (95% CI) Mean ICER (95% CI incremental net beneﬁt) CEAC probability of cost-eﬀectivenessc
Base case 246 202.91 (63.05–348.87) 0.024 (0.014–0.034) 8495.29 (34.31–514.35) 97.0%
Best casea 246 111.62 (−30.36 to 252.12) 0.024 (0.014–0.034) 4673.10 (124.63–607.62) 99.2%
Worst caseb 718 200.43 (152.95–251.69) 0.010 (0.006–0.014) 19,392.12 (−90.66 to 100.56) 54.2%
a As in base case but with the exclusion of training and equipment costs.
b Where data was missing a value of 0 was used for QALY data and £39.76 for other (non intervention) NHS costs. A cost for the intervention is also included for all
participants.
c CEAC=Cost-eﬀectiveness acceptability curve, where the associated probability of the intervention being cost-eﬀective is estimated for a threshold of £20,000
per QALY.
Fig. 2. Cost-eﬀectiveness acceptability curve for the Pharmacy Care Plan service.
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achieve.
The increase in PAM® score is positive for community pharmacy as it
demonstrates pharmacists' ability to motivate and empower patients
with long-term conditions. To our knowledge, this is the ﬁrst commu-
nity pharmacy evaluation to use this approach and as a result these
ﬁndings warrant further exploration in this settings. However, this is a
positive start to the use of this tool in this setting. With the link between
patient activation and improved health outcomes, patient experience
and reduced costs13–17 becoming more ﬁrmly established it is clear that
this approach is one that requires further investigation in the context of
primary care in the UK. By moving from the lowest activation level to
the highest estimates suggest that healthcare costs can be reduced by up
to 21%.15
Even when using worst case estimates this service is estimated to be
cost-eﬀective in relation to NICE thresholds.31 Despite the intensive
nature of the service, with multiple consultations over an extended
period of time, costs were kept low by making use of the whole phar-
macy team including HCAs obtaining clinical measurements instead of
the pharmacist. This is something that has been explored with other
pharmacy services, for example, as part of health living pharmacies51
and NHS Health Checks.52
In a previous publication, pharmacists reported a willingness to
deliver this service but also concerns regarding time commitment and
support.18 Despite this, the service managed to demonstrate an im-
provement to patient care and outcomes. This service was delivered by
a small number of well-motivated pharmacists and pharmacy staﬀ and
in order to be successfully implemented on a larger scale and achieve
similar outcomes, appropriate remuneration and support needs to be
provided.
Although there are few other examples of complex interventions of
this nature being provided and evaluated within the community phar-
macist setting, the previous work carried out by the CPF team to
evaluate other services focused on long-term conditions also demon-
strated favourable clinical and cost-eﬀectiveness results.5,6 Taken to-
gether, this suggests that community pharmacies are likely to represent
a cost-eﬀective use of NHS resources.
8. Conclusion
Enrollment on the PCP service was generally associated with an
improvement over 12 months in key clinical and process metrics, in-
cluding statistically signiﬁcant improvements in patient activation,
adherence, blood pressure and quality of life. Results also suggest that
the service would be cost-eﬀective to the health service (below the
£20,000 per QALY threshold value) even when using worst case as-
sumptions. The vast majority of patients set goals as part of the PCP
service, suggesting that pharmacists were able to engage with patient's
understanding of what health outcomes were important to them, and in
many cases, help patient's to achieve them. Further research needs to be
conducted to determine the eﬀect of goal setting on patient activation
together with qualitative work to understand how professionals and
patients responded to the use of the PAM® measure in practice.
Ethics approval
Approval for this service evaluation was provided by the Faculty of
Medicines and Health Sciences Ethics Committee at the University of
East Anglia (UEA) (Reference: 20142015/39/SE) before commence-
ment. Patients provided written consent to participate in the service.
Funding
The study design and implementation was funded by the
Community Pharmacy Future (CPF) group. The CPF group also paid a
consultancy fee to the team at UEA (MT, DW) to provide advice on
service design, to support training and to undertake the evaluation for
this service. The CPF research team (CLK and TT) are both employees
receiving salaries from Boots UK. The speciﬁc roles of these authors are
articulated in the 'author contributions' section.
Funding sources
The design and implementation of this project was funded by the
CPF group, with support from an educational grant from Pﬁzer.
Authors' contributions
All authors contributed to conceptualisation of the project and de-
velopment of the methodology. CK and TT contributed to study man-
agement, data collection and paper editing and review. MT performed
formal analysis and original manuscript preparation. DW and GB per-
formed formal analysis and contributed to review and editing of the
manuscript. DW was responsible for the academic supervision of the
project.
Competing interests
We have the following interests. The team at UEA (MT, DW, GB)
were paid a consultancy fee to provide advice, training and evaluation
for this service by the Community Pharmacy Future (CPF) group. The
CPF group (the funders) designed and implemented the service and had
sight and approved the submission to the journal. CLK and TT are
employees of Boots UK (and part of CPF group) and were part of the
evaluation team who were involved in the study design, data collection
and analysis, decision to publish, and preparation of the manuscript.
There are no patents, products in development or marketed products to
declare.
Declaration of interest
CK and TT are employees of Boots UK Ltd. MT, DW and GB are
employees of UEA. UEA was remunerated by the CPF team to manage
the academic evaluation of the CPF services.
Acknowledgements
The CPF team would like to thank contributors and advisors to the
project together with the pharmacists and patients who provided and
participated in the service. In particular, the team acknowledges the
contribution made by Pﬁzer. and the Pharmaceutical Services
Negotiating Committee (PSNC) in training of the pharmacy teams.
License agreements for use of the ©MMAS and the PAM® were obtained
prior to conducting this project. Use of the ©MMAS is protected by US
copyright laws. Permission for use is required. A license agreement is
available from: Donald E. Morisky, ScD, ScM, MSPH, Professor,
Department of Community Health Sciences, UCLA Fielding School of
Public Health, 650 Charles E. Young Drive South, Los Angeles, CA
90095-1772, dmorisky@ucla.edu.
References
1. Oﬃce for National Statistics. National Life Tables, UK: 2013–2015. 2016; 2016http://
www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/
lifeexpectancies/bulletins/nationallifetablesunitedkingdom/20132015, Accessed
date: 29 November 2016.
2. NHS England. Five Year Forward View. 2014; 2014https://www.england.nhs.uk/wp-
content/uploads/2014/10/5yfv-web.pdf, Accessed date: 29 November 2016.
3. NHS England. General Practice Forward View. 2016; 2016https://www.england.nhs.
uk/wp-content/uploads/2016/04/gpfv.pdf, Accessed date: 29 November 2016.
4. The King's Fund. Understanding Pressures in General Practice. 2016; 2016https://www.
kingsfund.org.uk/sites/ﬁles/kf/ﬁeld/ﬁeld_publication_ﬁle/Understanding-GP-
pressures-Kings-Fund-May-2016.pdf, Accessed date: 29 November 2016.
5. Twigg MJ, Wright D, Barton GR, Thornley T, Kerr C. The four or more medicines
(FOMM) support service: results from an evaluation of a new community pharmacy
service aimed at over-65s. Int J Pharm Pract. 2015;23(6):407–414.
M.J. Twigg et al. Research in Social and Administrative Pharmacy xxx (xxxx) xxx–xxx
8
6. Wright D, Twigg M, Barton G, Thornley T, Kerr C. An evaluation of a multi-site
community pharmacy-based chronic obstructive pulmonary disease support service.
Int J Pharm Pract. 2015;23(1):36–43.
7. Department of Health. Equity and Excellence: Liberating the NHS. London: The
Stationery Oﬃce; 2010.
8. The Health Foundation. Person Centred Care Made Simple: What Everyone Should Know
about Person Centred Care. London: The Health Foundation,; 2014.
9. The King's Fund. From Vision to Action: Making Patient-centred Care a Reality. London:
The King's Fund; 2012.
10. Royal Pharmaceutical Society. Improving Care for People with Long Term Conditions.
2016; 2016http://www.rpharms.com/policy-pdfs/32.-long-term-conditions-report.
pdf, Accessed date: 8 November 2016.
11. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient
Activation Measure (PAM): conceptualizing and measuring activation in patients and
consumers. Health Serv Res. 2004;39(4p1):1005–1026.
12. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short
form of the patient activation measure. Health Serv Res. 2005;40(6p1):1918–1930.
13. Hibbard J, Gilburt H. Supporting People to Manage Their Health: an Introduction to
Patient Activation. London: The King's Fund; 2014.
14. Greene J, Hibbard JH. Why does patient activation matter? An examination of the
relationships between patient activation and health-related outcomes. J Gen Intern
Med. 2012;27(5):520–526.
15. Hibbard JH, Greene J, Overton V. Patients with lower activation associated with
higher costs; delivery systems should know their patients'‘scores’. Health Aﬀ.
2013;32(2):216–222.
16. Remmers C, Hibbard J, Mosen DM, Wagenﬁeld M, Hoye RE, Jones C. Is patient ac-
tivation associated with future health outcomes and healthcare utilization among
patients with diabetes? J Ambul Care Manag. 2009;32(4):320–327.
17. Mitchell SE, Gardiner PM, Sadikova E, et al. Patient activation and 30-day post-
discharge hospital utilization. J Gen Intern Med. 2014;29(2):349–355.
18. Twigg MJ, Wright D, Kirkdale CL, Desborough JA, Thornley T. The UK Pharmacy
Care Plan service: description, recruitment and initial views on a new community
pharmacy intervention. PLoS One. 2017;12(4) e0174500.
19. National Institute for Health and Care Excellence. Hypertension: clinical manage-
ment of primary hypertension in adults. Clinical guideline. 2011;127.
20. National Institute for Health and Care Excellence (NICE). Lipid Modiﬁcation: cardio-
vascular Risk Assessment and the Modiﬁcation of Blood Lipids for the Primary and
Secondary Prevention of Cardiovascular Disease CG181. 2014; 2014http://www.nice.
org.uk/guidance/cg181, Accessed date: 12 August 2014.
21. NICE. Type 2 diabetes. The Management of Type 2 Diabetes (CG87). London: National
Institute of Health and Clinical Excellence; 2009.
22. O'Mahony D, Gallagher P, Ryan C, et al. STOPP & START criteria: a new approach to
detecting potentially inappropriate prescribing in old age. Eur Geriatric Med.
2010;1(1):45–51.
23. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the
United Kingdom: independent and external validation of an updated version of
QRISK2. BMJ. 2012:344.
24. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication
adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–354.
25. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medi-
cation adherence scale versus pharmacy ﬁll rates in seniors with hypertension. Am J
Manag Care. 2009;15(1):59–66.
26. Morisky D, DiMatteo M. Improving the measurement of self-reported medication
nonadherence: ﬁnal response. J Clin Epidemiol. 2011;64:258–263.
27. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the
new ﬁve-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–1736.
28. ClinRisk Ltd. QRisk2(R) scoring webpage. 2016; 2016https://qrisk.org/2016/.
29. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. University of Kent; 2015.
30. Department of Health. National Schedule of Reference Costs 2014-15. 2015;
2015https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-
2015.
31. NICE. Guide to the Methods of Technology Appraisal 2013. National Institute of Health
and Clinical Excellence (NICE) publications; 2013.
32. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the
Economic Evaluation of Health Care Programmes. fourth ed. New York: Oxford
University Press; 2015.
33. Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing Health-related Quality of
Life: an EQ-5D-5L Value Set for England. School of Health and Related Research
(Univsity of Sheﬃeld): Health Economics & Decision Science (HEDS); 2016
Discussion Paper Series.
34. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-ef-
fectiveness analysis: the importance of controlling for baseline utility. Health Econ.
2005;14:487–496.
35. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with
multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med
Decis Making. 2003;23:341–350.
36. Fenwick E, O'Brien BJ, Briggs AH. Cost-eﬀectiveness acceptability curves-facts, fal-
lacies and frequently asked questions. Health Econ. 2004;13:405–415.
37. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman and Hall;
1993.
38. Heyse JF, Cook JR, Carides GW. Statistical considerations in analysing health care
resource utilization and cost data. In: Drummond M, McGuire A, eds. Economic
Evaluation in Health Care. Oxford: Oxford University; 2001.
39. Stinnett AA, Mullahy J. Net health beneﬁts: a new framework for the analysis of
uncertainty in cost-eﬀectiveness analysis. Med Decis Making. 1998;18:S68–S80.
40. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic
evaluation of health care technologies. J Health Econ. 1999;18(3):341–364.
41. Matsuyama JR, Mason BJ, Jue SG. Pharmacists' interventions using an electronic
medication-event monitoring device's adherence data versus pill counts. Ann
Pharmacother. 1993;27(7–8):851–855.
42. Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with
chronic mental illness: a critical examination of the self-report methodology. Am J
Psychiatr. 1997;154(1):99–105.
43. Ramsey S, Willke RJ, Glick H, et al. Cost-eﬀectiveness analysis alongside clinical
trials II-An ISPOR good research practices task force report. Value Health.
2015;18:161–172.
44. Thorn JC, Coast J, Cohen D, et al. Resource-use measurement based on patient recall:
issues and challenges for economic evaluation. Appl Health Econ Health Pol.
2013;10:1–7.
45. Shilts MK, Horowitz M, Townsend MS. Goal setting as a strategy for dietary and
physical activity behavior change: a review of the literature. Am J Health Promot.
2004;19(2):81–93.
46. Bodenheimer T, Handley MA. Goal-setting for behavior change in primary care: an
exploration and status report. Patient Educ Counsel. 2009;76(2):174–180.
47. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic
control and drug adherence in an indigent population. Diabetes Care.
2002;25(6):1015–1021.
48. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key
factor in achieving blood pressure control and good clinical outcomes in hyperten-
sive patients. Curr Op Cardiol. 2004;19(4):357–362.
49. Vestbo J, Anderson JA, Calverley PMA, et al. Adherence to inhaled therapy, mortality
and hospital admission in COPD. Thorax. 2009;64(11):939–943.
50. Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies,
health outcomes and costs in patients with asthma and COPD. Respir Med.
2013;107(10):1481–1490.
51. Brown D, Portlock J, Rutter P, Nazar Z. From community pharmacy to healthy living
pharmacy: positive early experiences from Portsmouth, England. Res Soc Adm Pharm.
2014;10(1):72–87.
52. McNaughton RJ, Oswald NT, Shucksmith JS, Heywood PJ, Watson PS. Making a
success of providing NHS Health Checks in community pharmacies across the Tees
Valley: a qualitative study. BMC Health Serv Res. 2011;11(1):222.
M.J. Twigg et al. Research in Social and Administrative Pharmacy xxx (xxxx) xxx–xxx
9
